-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GZ34Qee9cT8gPYfUXTF12K97syBZ9J8Ijq6FXiUglmT/qoxr/yqLEDcopiQVoY18 8MZoJqP+iZ2FAh1hm78/5A== 0001209191-05-023539.txt : 20050503 0001209191-05-023539.hdr.sgml : 20050503 20050503165055 ACCESSION NUMBER: 0001209191-05-023539 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050501 FILED AS OF DATE: 20050503 DATE AS OF CHANGE: 20050503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: STEVENSON KATHARINE BERGHUIS CENTRAL INDEX KEY: 0001232227 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15190 FILM NUMBER: 05795743 BUSINESS ADDRESS: STREET 1: C/O NORTEL NETWORKS STREET 2: 8200 DIXIE ROAD STE 100 CITY: BRAMPTON ONTARIO STATE: A6 ZIP: L6T 5P6 BUSINESS PHONE: 9058631160 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: OSI PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000729922 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133159796 STATE OF INCORPORATION: DE FISCAL YEAR END: 1204 BUSINESS ADDRESS: STREET 1: 58 SOUTH SERVICE RD. STREET 2: SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 BUSINESS PHONE: 631-962-2000 MAIL ADDRESS: STREET 1: 58 SOUTH SERVICE RD. STREET 2: SUITE 110 CITY: MELVILLE STATE: NY ZIP: 11747 FORMER COMPANY: FORMER CONFORMED NAME: ONCOGENE SCIENCE INC DATE OF NAME CHANGE: 19920703 4 1 doc4.xml FORM 4 SUBMISSION X0202 4 2005-05-01 0 0000729922 OSI PHARMACEUTICALS INC OSIP 0001232227 STEVENSON KATHARINE BERGHUIS C/O OSI PHARMACEUTICALS, INC. 58 SOUTH SERVICE RD., SUITE 110 MELVILLE NY 11747 1 0 0 0 Common Stock 2005-05-01 4 A 0 833 0.00 A 833 D Stock Option (Right to Buy) 47.34 2005-05-01 4 A 0 50000 0.00 A 2006-05-01 2015-04-30 Common Stock 50000 50000 D Reflects a grant of restricted stock under the Stock Purchase Plan for Non-Employee Directors, which vests over eleven-months in equal monthly increments and any unvested shares are subject to forfieture upon termination of the director's services prior to the end of the eleven-month term. The grant is exempt under Rule 16b-3. One third of the stock option will become exercisable one year after the date of the grant and the remainder will vest ratably on a monthly basis over the succeeding 24 months. The stock option was granted pursuant to one of the Issuer's incentive and non-qualified stock option plans and is exempt under Rule 16b-3. Includes only options with the same termination date. Robert L. Van Nostrand by Power of Attorney 2005-05-03 -----END PRIVACY-ENHANCED MESSAGE-----